Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance - PubMed (original) (raw)

Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance

Kristi Hendrickson et al. Radiother Oncol. 2011 Dec.

Abstract

Background and purpose: Positron emission tomography (PET) imaging with [F-18] fluoromisonidazole (FMISO) has been validated as a hypoxic tracer. Head and neck cancer exhibits hypoxia, inducing aggressive biologic traits that impart resistance to treatment. Delivery of modestly higher radiation doses to tumors with stable areas of chronic hypoxia can improve tumor control. Advanced radiation treatment planning (RTP) and delivery techniques such as intensity modulated radiation therapy (IMRT) can deliver higher doses to a small volume without increasing morbidity. We investigated the utility of co-registered FMISO-PET and CT images to develop clinically feasible RTPs with higher tumor control probabilities (TCP).

Materials and methods: FMISO-PET images were used to determine hypoxic sub-volumes for boost planning. Example plans were generated for 10 of the patients in the study who exhibited significant hypoxia. We created an IMRT plan for each patient with a simultaneous integrated boost (SIB) to the hypoxic sub-volumes. We also varied the boost for two patients.

Result: A significant (mean 17%, median 15%) improvement in TCP is predicted when the modest additional boost dose to the hypoxic sub-volume is included.

Conclusion: Combined FMISO-PET imaging and IMRT planning permit delivery of higher doses to hypoxic regions, increasing the predicted TCP (mean 17%) without increasing expected complications.

Published by Elsevier Ireland Ltd.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement

The authors confirm that there are no conflicts of interests, financial or otherwise, in conducting this research with FMISO-PET imaging and radiation therapy planning.

Figures

Fig. 1

Co-registered CT and FMISO-PET images in transaxial, sagittal, and coronal projections for BOT example patient.

Fig. 2

Isodose display on axial slices for SIB IMRT plan showing conformal 70-Gy dose around primary PTV (red) and 60-Gy dose around affected nodes (pink and blue). Hypoxic GTV (green) is covered by 80-Gy isodose. Parotid glands (orange and lilac) are avoided by high isodose lines.

Fig. 3

Dose volume histogram for plans without (dashed) and with (solid) 10-Gy boost to hypoxic GTV for the sample patient in Figs. 1 and 2.

Cited by

Hyperpolarizing Concentrated Metronidazole 15 NO2 Group over Six Chemical Bonds with More than 15 % Polarization and a 20 Minute Lifetime.
Shchepin RV, Birchall JR, Chukanov NV, Kovtunov KV, Koptyug IV, Theis T, Warren WS, Gelovani JG, Goodson BM, Shokouhi S, Rosen MS, Yen YF, Pham W, Chekmenev EY. Shchepin RV, et al. Chemistry. 2019 Jul 2;25(37):8829-8836. doi: 10.1002/chem.201901192. Epub 2019 May 30. Chemistry. 2019. PMID: 30964568 Free PMC article.
15N Hyperpolarization of Metronidazole Antibiotic in Aqueous Media Using Phase-Separated Signal Amplification by Reversible Exchange with Parahydrogen.
Sviyazov SV, Burueva DB, Chukanov NV, Razumov IA, Chekmenev EY, Salnikov OG, Koptyug IV. Sviyazov SV, et al. J Phys Chem Lett. 2024 May 23;15(20):5382-5389. doi: 10.1021/acs.jpclett.4c00875. Epub 2024 May 13. J Phys Chem Lett. 2024. PMID: 38738984
Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET.
Georg P, Andrzejewski P, Baltzer P, Daniel M, Wadsak W, Mitterhauser M, Sturdza A, Majercakova K, Karanikas G, Pötter R, Hacker M, Helbich T, Georg D, Pinker K. Georg P, et al. Mol Imaging Biol. 2018 Feb;20(1):160-169. doi: 10.1007/s11307-017-1087-5. Mol Imaging Biol. 2018. PMID: 28540524 Free PMC article.
Hypoxia imaging and radiotherapy: bridging the resolution gap.
Grimes DR, Warren DR, Warren S. Grimes DR, et al. Br J Radiol. 2017 Aug;90(1076):20160939. doi: 10.1259/bjr.20160939. Epub 2017 May 25. Br J Radiol. 2017. PMID: 28540739 Free PMC article. Review.
Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview.
Sharma P, Mukherjee A. Sharma P, et al. Ann Transl Med. 2016 Feb;4(3):53. doi: 10.3978/j.issn.2305-5839.2016.01.26. Ann Transl Med. 2016. PMID: 26904575 Free PMC article. Review.

References

1. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391–398. - PubMed
1. Rajendran JG, Mankoff DA, O'Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245–2252. - PubMed
1. Sovik A, Malinen E, Bruland OS, Bentzen SM, Olsen DR. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Phys Med Biol. 2007;52:499–513. - PubMed
1. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radat Oncol Biol Phys. 1997;38:285–289. - PubMed
1. Adam M, Gabalski EC, Bloch DA, Ochlert JW, Brown JM, Elsaid AA, Pinto HA, Terris DJ. Tissue oxygen distribution in head and neck cancer patients. Head Neck. 1999;21:146–153. - PubMed

Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance - PubMed (original) (raw)